Harmony Biosciences (NASDAQ:HRMY) Insider Sells 1,800 Shares of Stock

Posted by Stanley Muller on Sep 18th, 2026

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Get Free Report) insider Kumar Budur sold 1,800 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $43.01, for a total transaction of $77,418.00. Following the completion of the sale, the insider owned 13,115 shares of the company’s stock, valued at $564,076.15. This trade represents a 12.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Kumar Budur also recently made the following trade(s):

On Thursday, September 17th, Kumar Budur sold 800 shares of Harmony Biosciences stock. The stock was sold at an average price of $43.00, for a total transaction of $34,400.00.
On Friday, September 18th, Kumar Budur sold 35,852 shares of Harmony Biosciences stock. The shares were sold at an average price of $43.05, for a total transaction of $1,543,428.60.
On Friday, September 4th, Kumar Budur sold 5,500 shares of Harmony Biosciences stock. The shares were sold at an average price of $41.98, for a total transaction of $230,890.00.
On Tuesday, September 8th, Kumar Budur sold 28,454 shares of Harmony Biosciences stock. The shares were sold at an average price of $42.96, for a total transaction of $1,222,383.84.

Harmony Biosciences Price Performance

Shares of NASDAQ:HRMY traded down $0.72 during trading on Friday, hitting $42.02. 3,658,124 shares of the stock were exchanged, compared to its average volume of 869,461. The company has a market cap of $2.45 billion, a PE ratio of 13.64, a P/E/G ratio of 0.39 and a beta of 0.93. The company has a current ratio of 3.48, a quick ratio of 3.45 and a debt-to-equity ratio of 0.13. The company has a fifty day moving average price of $38.46 and a two-hundred day moving average price of $33.68. Harmony Biosciences Holdings, Inc. has a 12-month low of $25.52 and a 12-month high of $43.49.

Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported $1.28 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.32. The firm had revenue of $261.28 million during the quarter, compared to the consensus estimate of $250.77 million. Harmony Biosciences had a return on equity of 20.06% and a net margin of 18.88%.Harmony Biosciences’s quarterly revenue was up 30.3% on a year-over-year basis. During the same period last year, the business posted $0.92 EPS. On average, analysts forecast that Harmony Biosciences Holdings, Inc. will post 3.77 EPS for the current year.

Analyst Upgrades and Downgrades

HRMY has been the subject of a number of research analyst reports. Needham & Company LLC raised their price target on Harmony Biosciences from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Wolfe Research initiated coverage on shares of Harmony Biosciences in a research report on Wednesday, August 26th. They issued an “outperform” rating and a $60.00 price objective on the stock. Zacks Research cut shares of Harmony Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 11th. Wall Street Zen upgraded shares of Harmony Biosciences from a “buy” rating to a “strong-buy” rating in a report on Sunday, August 16th. Finally, Weiss Ratings upgraded shares of Harmony Biosciences from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday, August 17th. Five analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Harmony Biosciences presently has an average rating of “Hold” and an average price target of $47.11.

View Our Latest Analysis on Harmony Biosciences

Hedge Funds Weigh In On Harmony Biosciences

Several hedge funds have recently bought and sold shares of HRMY. EverSource Wealth Advisors LLC lifted its position in shares of Harmony Biosciences by 589.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 752 shares of the company’s stock valued at $28,000 after acquiring an additional 643 shares in the last quarter. Leonteq Securities AG purchased a new stake in Harmony Biosciences during the 4th quarter worth about $30,000. Allworth Financial LP increased its position in Harmony Biosciences by 286.7% during the 4th quarter. Allworth Financial LP now owns 812 shares of the company’s stock worth $30,000 after purchasing an additional 602 shares in the last quarter. Nykredit A S acquired a new position in Harmony Biosciences in the 2nd quarter valued at about $33,000. Finally, Clearstead Advisors LLC raised its stake in Harmony Biosciences by 145.9% in the 4th quarter. Clearstead Advisors LLC now owns 1,178 shares of the company’s stock valued at $44,000 after purchasing an additional 699 shares during the last quarter. Hedge funds and other institutional investors own 86.23% of the company’s stock.

About Harmony Biosciences

(Get Free Report)

Harmony Biosciences Holdings, Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients with rare neurological disorders. The company was founded in 2017 and is headquartered in Plymouth Meeting, Pennsylvania, with an emphasis on conditions that are often underserved by traditional pharmaceutical research.

Harmony’s principal product is WAKIX (pitolisant), a first-in-class histamine H3 receptor antagonist/inverse agonist approved by the U.S.